At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 363 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Ixekizumab 80 mg Q4Wfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Placebo, Ixekizumab 80 mg Q4W, and 1 other intervention for Psoriatic Arthritis. Completed, enrolled 363 participants across 109 sites in 10 countries.
Detailed Summary
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Czechia, France, Germany, Italy, Poland, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedJan 2015
Primary CompletionSep 2016
Study CompletionJun 2019
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartDec 31, 2014
Primary CompletionSep 9, 2016
Study CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.4 years ago
Interventions
Placebodrug
Administered SC
Ixekizumab 80 mg Q4Wdrug
Administered SC
Ixekizumab 80 mg Q2Wdrug
Administered SC